Truist upgraded Globus Medical (GMED) to Buy from Hold with a price target of $93, up from $65. The firm has greater confidence in the company’s mid- to high-single-digit revenue growth outlook with low- to mid-teens earnings growth. Nevro accretion is getting pulled forward nearly one year ahead of expectations while Globus is seeing accelerating trends in the core spine business, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED: